{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:31Z","timestamp":1787030131122,"version":"build-2736575974"},"reference-count":55,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Direct-acting antiviral therapies can cure most people with hepatitis C virus (HCV) infection with little need for testing or monitoring. A major challenge to eliminating HCV is ensuring patients complete all steps of care, including confirmation of cure. We assessed the concordance of sustained virologic response (SVR) at 4 weeks (SVR4) and 12 weeks (SVR12) post-treatment to evaluate the viability of SVR4 as a predictor of cure in patients treated with sofosbuvir (SOF)\/velpatasvir (VEL). We conducted a retrospective analysis of patients from the Phase 3 ASTRAL-1, -2, and -3 programs and a historical cohort from the Louisiana Department of Health Sexually Transmitted Infection (STI)\/HIV\/Hepatitis Program claims database. Concordance analyses were performed for patients with both SVR4 and SVR12 data. The concordance analysis in the ASTRAL studies included 1015 patients; 1005 and 1002 achieved SVR4 and SVR12, respectively. Among SVR4 achievers, 3 failed to maintain SVR12, while all (10\/10) patients who did not achieve SVR4 also failed SVR12. In the real-world cohort, 479\/509 (94%) patients achieved SVR4 and 485\/509 (95%) achieved SVR12. Of those with SVR4, 7 failed SVR12; 17 of 30 patients who did not achieve SVR4 also failed SVR12. High concordance between SVR4 and SVR12 was observed in both ASTRAL and the real-world dataset, supporting the use of SVR4 as a predictor of long-term SVR in patients with HCV infection treated with SOF\/VEL. Streamlining cure confirmation by shifting SVR determination from week 12 to week 4 post-treatment may reduce patient loss to follow-up.<\/jats:p>","DOI":"10.3390\/v18020269","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:00:52Z","timestamp":1771840852000},"page":"269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir\/Velpatasvir"],"prefix":"10.3390","volume":"18","author":[{"given":"Gia","family":"Landry","sequence":"first","affiliation":[{"name":"Lane Regional Medical Center, Zachary, LA 70791, USA"},{"name":"Louisiana State University Health, Baton Rouge, LA 70805, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reau","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Scherbakovsky","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah","family":"Black","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candido","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-6732","authenticated-orcid":false,"given":"Renee-Claude","family":"Mercier","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Ni","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-9200","authenticated-orcid":false,"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Joseph, 13008 Marseille, France"},{"name":"INSERM UMR 1252 IRD SESSTIM Aix Marseille Universit\u00e9, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mangia","sequence":"additional","affiliation":[{"name":"Liver Unit, IRCCS Fondazione \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"ref_2","unstructured":"World Health Organization (2025, April 07). Hepatitis C, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int."},{"key":"ref_4","unstructured":"World Health Organization (2025, April 07). Global Health Strategy on Viral Hepatitis 2016\u20132021, Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_6","unstructured":"World Health Organization (2025, April 08). Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics, Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/363590\/9789240052734-eng.pdf?sequence=1."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_8","unstructured":"World Health Organization (2025, April 07). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection, Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf?ua=1."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/14656566.2017.1282459","article-title":"A pangenotypic, single tablet regimen of sofosbuvir\/velpatasvir for the treatment of chronic hepatitis C infection","volume":"18","author":"Weisberg","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/M19-3860","article-title":"World Health Organization guidelines on treatment of hepatitis C virus infection: Best practice advice from the American College of Physicians","volume":"174","author":"Abraham","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_11","first-page":"629","article-title":"Care of patients following cure of hepatitis C virus infection","volume":"14","author":"Terrault","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/liv.14469","article-title":"Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus","volume":"40","author":"Aleman","year":"2020","journal-title":"Liver Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvh.13228","article-title":"Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies","volume":"27","author":"Darvishian","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejim.2022.04.024","article-title":"Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination","volume":"101","author":"Isfordink","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s43856-022-00077-9","article-title":"A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid","volume":"2","author":"Lazarus","year":"2022","journal-title":"Commun. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e5455","DOI":"10.1590\/1414-431x20165455","article-title":"Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic","volume":"49","author":"Mendes","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zarebska-Michaluk, D., Brzdek, M., Tronina, O., Janocha-Litwin, J., Sitko, M., Piekarska, A., Klapaczynski, J., Parfieniuk-Kowerda, A., Sobala-Szczygiel, B., and Tudrujek-Zdunek, M. (2024). Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination. BMC Med., 22.","DOI":"10.1186\/s12916-024-03753-w"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12954-021-00486-4","article-title":"Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City","volume":"18","author":"Ziff","year":"2021","journal-title":"Harm Reduct. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4254\/wjh.v16.i8.1091","article-title":"Bridging the gap: Addressing disparities in hepatitis C screening, access to care, and treatment outcomes","volume":"16","author":"Alenzi","year":"2024","journal-title":"World J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Facente, S.N., Grinstein, R., Bruhn, R., Kaidarova, Z., Wilson, E., Hecht, J., Burk, K., Grebe, E., and Morris, M.D. (2022). Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267902"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/cid\/ciaa571","article-title":"Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study","volume":"73","author":"Valerio","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.4103\/jfmpc.jfmpc_788_22","article-title":"A retrospective study to find the prevalence of HIV, HCV, and dual HIV-HCV infection in the prison inmates","volume":"11","author":"Singh","year":"2022","journal-title":"J. Family Med. Prim. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","article-title":"Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees","volume":"388","author":"Dolan","year":"2016","journal-title":"Lancet"},{"key":"ref_25","first-page":"154","article-title":"Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review","volume":"15","author":"Burgess","year":"2016","journal-title":"Ann. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.23444","article-title":"Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin","volume":"51","author":"Stern","year":"2010","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_28","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2025, September 08). Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for TREATMENT guidance for Industry, Available online: https:\/\/www.fda.gov\/files\/drugs\/published\/Chronic-Hepatitis-C-Virus-Infection---Developing-Direct-Acting-Antiviral-Drugs-for-Treatment-Guidance-for-Industry.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials","volume":"28","author":"Gane","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lin, C.P., Liang, P.C., Huang, C.I., Yeh, M.L., Hsu, P.Y., Hsu, C.T., Wei, Y.J., Liu, T.W., Hsieh, M.Y., and Hou, N.J. (2021). Concordance of SVR12, SVR24, and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245479"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e29675","DOI":"10.1002\/jmv.29675","article-title":"Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals","volume":"96","author":"Liu","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Milosevic, I., Filipovic, A., Beronja, B., Mitrovic, N., Ruzic, M., Simic, J., Knezevic, N., Pete, M., Todorovic, N., and Nikolic, N. (2024). Optimizing hepatitis C treatment monitoring: Is sustained virologic response at 4 weeks becoming the new standard?. Microorganisms, 12.","DOI":"10.3390\/microorganisms12102050"},{"key":"ref_33","unstructured":"(2025, April 08). Hepatitis C Virus Infection Consensus Statement Working Group. Australian Recommendations for the Management of Hepatitis C Virus Infection: A Consensus Statement. Available online: https:\/\/www.hepcguidelines.org.au\/wp-content\/uploads\/2022\/11\/hepatitis-C-virus-infection-a-consensus-statement-2022.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/sjg.sjg_333_23","article-title":"SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024","volume":"30","author":"Alghamdi","year":"2024","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sheehan, Y., Akhil, G., Sheehan, J., Maduka, N., Altice, F.L., Alves da Costa, F., Cox, S., Elsharkawy, A.M., Salah, E., and Stoov\u00e9, M. (2025, April 08). Global Guidelines for Viral Hepatitis Service Delivery in Prisons. Available online: https:\/\/inhsu.org\/wp-content\/uploads\/2024\/09\/Global-Guidelines_FINAL.pdf.","DOI":"10.1016\/S1473-3099(25)00630-9"},{"key":"ref_36","unstructured":"Aronsohn, A. (2024, January 15\u201319). AASLD\/IDSA guidance update: New SVR guidance and test and treat algorithm. Proceedings of the AASLD: The Liver Meeting, San Diego, CA, USA."},{"key":"ref_37","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (2025, May 15). Hepatitis C Test and Treat Follow up Visit. Available online: https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/HCV%20Test%20and%20Treat%20Final%20011725.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2025.01.013","article-title":"Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies","volume":"83","author":"Razavi","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: An open-label, phase 3 study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Buggisch, P., Wursthorn, K., Stoehr, A., Atanasov, P.K., Supiot, R., Lee, J., Ting, J., and Petersen, J. (2019). Real-world effectiveness and safety of sofosbuvir\/velpatasvir and ledipasvir\/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214795"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Charatcharoenwitthaya, P., Wongpaitoon, V., Komolmit, P., Sukeepaisarnjaroen, W., Tangkijvanich, P., Piratvisuth, T., Sanpajit, T., Sutthivana, C., Bunchorntavakul, C., and Sobhonslidsuk, A. (2020). Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01196-0"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Huang, Y.T., Hsieh, Y.Y., Chen, W.M., Tung, S.Y., Wei, K.L., Shen, C.H., Chang, K.C., Lu, C.K., Yen, C.W., and Lu, S.N. (2021). Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01837-y"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12072-021-10158-x","article-title":"Sofosbuvir\/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: Real-world data in Taiwan","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ofaa055","DOI":"10.1093\/ofid\/ofaa055","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: A population-based cohort study","volume":"7","author":"Wilton","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","article-title":"Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial","volume":"65","author":"Younossi","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cgh.2017.11.023","article-title":"Patient-reported outcomes following treatment of chronic hepatitis C virus infection with sofosbuvir and velpatasvir, with or without voxilaprevir","volume":"16","author":"Younossi","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies","volume":"64","author":"Sarrazin","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/ciae627","article-title":"Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial","volume":"80","author":"Han","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2430024","DOI":"10.1001\/jamanetworkopen.2024.30024","article-title":"Hepatitis C virus reinfection among people who inject drugs: Long-term follow-up of the HERO study","volume":"7","author":"Litwin","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.cgh.2020.06.061","article-title":"Spontaneous clearance after relapse following direct-acting antiviral treatment for chronic HCV infection","volume":"19","author":"Kuriry","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:13:33Z","timestamp":1771910013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020269"],"URL":"https:\/\/doi.org\/10.3390\/v18020269","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]}}}